Maria is a postdoctoral fellow from Madrid, Spain. She received her PhD in Cellular Biology and Genetics under the supervision of Dr. Andrés Hidalgo at the Universidad Autónoma de Madrid (Spain) in 2015. Her PhD studies were focused on understanding the mechanisms of neutrophil aging and how the natural clearance of aged neutrophils triggers the homeostatic release of hematopoietic progenitors from bone marrow into the blood. She joined Dr.Merad laboratory in April 2015, after being awarded a long-term postdoctoral fellowship from the Human Frontiers Science Program. During her postdoctoral research she is currently interested in the role of macrophage ontogeny in the context of lung adenocarcinoma progression in primary tumors.
Fundings : Human Frontiers Science Program
Jalal is a Holman Research Pathway Resident in the Department of Radiation Oncology. His work is focused on targeting the tumor microenvironment to improve anti-tumor immune responses by Chimeric Antigen Receptor (CAR) T cells.
Fundings : Lung Cancer Research Foundation and the American Society for Clinical Oncology
Assaf Magen, Ph.D. is a computational scientist (bioinformatics) developing computational strategies to mine single-cell genomics and multiplex imaging data of human malignancies. During his doctoral work, he identified novel subsets of immune cells and their prognostic value in murine and human tumors. He is currently working on characterizing the crosstalk between immune, malignant and stromal cells, and how their interactions may affect tumor development and patient response to therapy.
Maxime is a postdoctoral fellow who is part of both the Merad Lab and the Brown Lab. He is taking advantage of the Jedi mice (developed by the Brown laboratory) to study the mechanisms of cytotoxic CD8+ T cell (CTLs)-mediated tumor regression in vivo. He is particularly interested in the interactions between CTLs and cancer-initiating cells.
Fundings: Belgian American Education Foundation
Alfonso is a postdoctoral fellow from Madrid, Spain. During his PhD studies in the University of Navarra (Pamplona, Spain), he investigated the role type 1 conventional dendritic cells play in cancer immunity. In conjunction with Brian Brown’s lab, he is currently working on the development of novel myeloid cell-targeted therapies in the context of cancer immunotherapy.
Gurkan received his master’s degree in molecular biology and genetics from Koc University (Istanbul, Turkey) and his doctorate in oncological sciences from the University of Utah School of Medicine. He joined the Merad and the Brown labs at Mount Sinai to study the role of cancer genetics in tumor immunity. He is fascinated by the nature of the complex interactions between cancer cells and immune cells. He thinks that a better understanding of the incredibly dynamic co-evolution of cancer cells and the immune system will eventually make most cancers if not all manageable diseases.
Funding: The National Cancer Institute